Schizophrenia — Disease Profile

Introduction

Definition

"Schizophrenia, the prototypical psychotic disorder, necessarily includes symptoms of psychosis ('positive' symptoms) and also often includes 'negative symptoms' such as affective flattening, abulia, apathy, and social withdrawal. The level of functioning is impaired in one or more realms." — Goldman-Cecil Medicine, p. 234

Symptom Domains

DSM-5 Diagnostic Criteria

1. Two or more of the following, each present for a significant portion of time during a 1-month period, with at least one being items (a), (b), or (c):
   • (a) Delusions
   • (b) Hallucinations
   • (c) Disorganized speech
   • (d) Grossly disorganized or catatonic behavior
   • (e) Negative symptoms
2. Social/occupational dysfunction — level of functioning in work, interpersonal relations, or self-care markedly below prior level.
3. Duration — continuous signs of disturbance persist for at least 6 months (including at least 1 month of active-phase symptoms).
4. Exclusions — schizoaffective disorder, depressive or bipolar disorder with psychotic features, and psychosis attributable to substances or general medical conditions must be ruled out.

ICD-10 vs. DSM-5

Spectrum Concept

• Brief psychotic disorder — psychotic episode lasting < 1 month with full return to baseline
• Schizophreniform disorder — duration of 1–6 months
• Schizoaffective disorder — concurrent mood and psychotic symptoms
• Delusional disorder — non-bizarre delusions without other schizophrenic features
• Schizotypal personality disorder — subclinical perceptual distortions and odd cognitions

Neurobiology Underlying the Definition

• Dopamine hypothesis: Hyperfunction of mesolimbic dopaminergic pathways underlies positive symptoms; hypofunction in the mesocortical (prefrontal) dopaminergic system underlies negative and cognitive symptoms. All clinically effective antipsychotics block D2 receptors to some degree. — Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 320; Ganong's Review of Medical Physiology, p. 160
• Glutamate hypothesis: NMDA receptor hypofunction, particularly on GABAergic interneurons in the prefrontal cortex, disinhibits pyramidal neurons and mimics schizophrenic symptoms — an observation derived from the psychotomimetic effects of NMDA antagonists (phencyclidine, ketamine).
• Neurodevelopmental model: Subtle disruptions of cortical cytoarchitecture, without gliosis, found in postmortem brains suggest an early developmental insult rather than a degenerative process. Genetic factors (up to 50% heritability, involving multiple rare variants related to synaptic plasticity), prenatal immune activation, and obstetric complications converge on the developing brain. — Goldman-Cecil Medicine
• Neuroinflammation: Meta-analyses of over 85,000 subjects document modest but consistent elevations of CRP, IL-6, IL-8, and TNF-α in schizophrenia, particularly in first-episode, drug-naïve patients — implicating innate immune dysregulation as a pathogenic contributor. — Kaplan & Sadock's Comprehensive Textbook of Psychiatry, p. 678

• Goldman-Cecil Medicine International Edition, 2 Volume Set (Chapter 362)
• Kaplan & Sadock's Comprehensive Textbook of Psychiatry
• Kaplan and Sadock's Synopsis of Psychiatry
• Ganong's Review of Medical Physiology, 26th Edition, p. 160
• Goodman & Gilman's The Pharmacological Basis of Therapeutics, p. 320

Anatomy and Physiology of Schizophrenia

I. Structural Brain Anatomy

Gross Macrostructure

• Enlarged lateral and third ventricles — among the most replicated findings, present at illness onset and not simply a consequence of antipsychotic treatment.
• Reduced total gray matter volume, particularly in the frontal, temporal, and parietal lobes.
• Thinner cortical gray matter, with progressive thinning over the course of illness.

"Post-mortem studies add validity and point to a pathophysiology of reduced neuronal size and dendritic arborisation, which is multifactorial." — Lancet Psychiatry, 2025

Prefrontal Cortex (PFC)

• Increased neuronal density with smaller pyramidal somal cell volumes — not due to neuronal loss, but rather a reduction in surrounding neuropil (dendrites, axon terminals, synaptic contacts).
• Reduced dendritic spine density specifically in layer III pyramidal neurons, the primary site for integrating inputs from other cortical regions and the thalamus.
• Layer III pyramidal neurons serve as the main relay for cortico-cortical connectivity; their impaired arborization directly compromises information integration.
• Decreased expression of GAD67 (glutamate decarboxylase), the enzyme converting glutamate to GABA, indicating impaired GABAergic interneuron function in the PFC.
• Decreased glucose transporter expression (GLUT1, GLUT3) in DLPFC pyramidal neurons, pointing to disrupted cellular energy metabolism.

"Reductions in neuropil suggest that schizophrenia is associated with a quantitative deficit in neuronal connections... reductions in spine density in layer 3 of the PFC are consistently reported." — Kaplan & Sadock's Comprehensive Textbook of Psychiatry, p. 4535

Hippocampal Formation

• Meta-analyses report ~4% reductions in hippocampal volume, lateralized to the left side in many studies.
• Smaller pyramidal neurons are found in the hippocampus (but not in visual or motor cortex), suggesting region-specific pathology.
• Reduced dendritic spine density in hippocampal pathways has been reported.
• Hippocampal volume reduction is present at disease onset and progresses with illness advancement — suggesting both a neurodevelopmental origin and a progressive neurotoxic component.

Thalamus and Striatum

• The thalamus shows volume reductions, particularly in the mediodorsal nucleus, which relays information to and from the prefrontal cortex.
• The striatum (caudate, putamen, nucleus accumbens) is central to dopamine-mediated reward and motor circuits; imaging shows altered dopamine synthesis and release capacity in the striatum, particularly the ventral striatum (nucleus accumbens), which forms the mesolimbic terminal zone.

II. The Neurotransmitter Physiology

1. The Dopamine System (Primary Hypothesis)

A. Mesolimbic Pathway — Positive Symptoms

• Projects from VTA → nucleus accumbens (ventral striatum) and other limbic structures.
• Under normal conditions, mediates motivation, pleasure, and reward.
• In schizophrenia: hyperdopaminergia (excessive D2 receptor stimulation) in this pathway → hallucinations, delusions, paranoia (positive symptoms).
• Amphetamine (which floods the synapse with dopamine) reproduces paranoid psychosis; all antipsychotics block D2 receptors — this is the foundational pharmacological evidence.

B. Mesocortical Pathway — Negative and Cognitive Symptoms

• Projects from VTA → dorsolateral PFC (cognition/executive function) and ventromedial PFC (affect/emotion).
• Critically, mesocortical terminals lack presynaptic D2/D3 autoreceptors and dopamine transporters (DATs) — dopamine diffuses widely, acting primarily on D1 receptors (low sensitivity, requiring higher concentrations to activate).
• In schizophrenia: hypodopaminergia in the mesocortical projection to DLPFC → working memory deficits, executive dysfunction, avolition, flat affect (negative and cognitive symptoms).
• This hypodopaminergia is thought to be downstream of glutamate NMDA hypofunction (see below).

"DA hyperfunction in subcortical regions, most notably the striatum, has been associated with the positive symptoms of schizophrenia... the PFC of schizophrenic patients exhibits dopaminergic hypofunction, which has been associated with the more treatment-refractory negative/cognitive symptoms." — Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 320

Summary: Dopamine Imbalance in Schizophrenia

2. The Glutamate/NMDA System (Unifying Hypothesis)

• Cortical glutamate neurons → GABAergic parvalbumin interneurons (in PFC and hippocampus) → regulate pyramidal neuron output.

1. NMDA receptors on GABAergic interneurons in the PFC are hypofunctional (due to neurodevelopmental abnormalities, or mimicked by PCP/ketamine).
2. Loss of GABA interneuron activity → disinhibition of cortical pyramidal neurons.
3. Disinhibited pyramidal neurons release excess glutamate into downstream circuits.
4. Downstream glutamate excess → enhanced dopamine release in the mesolimbic pathway → positive symptoms.
5. Simultaneously, the mesocortical DA system is left underactive → negative/cognitive symptoms.

"NMDA receptor hypoactivity at GABAergic interneurons with loss of GABAergic inhibition in the prefrontal cortex... hyperactive glutamate output from the prefrontal cortex can hypothetically explain both positive and negative symptoms." — Stahl's Essential Psychopharmacology

• PCP (phencyclidine) and ketamine block NMDA receptors → reproduce the full schizophrenic syndrome including negative symptoms and cognitive deficits, not just psychosis.
• This contrasts with amphetamine (dopamine only), which produces mainly paranoid/positive symptoms.

3. The Serotonin System

• 5-HT₂A receptor hyperfunction at glutamate neurons in the cerebral cortex is the third major hypothesis.
• Psychedelics (LSD, psilocybin) act as 5-HT₂A agonists and produce visual hallucinations and altered reality — a serotonin-mediated model of psychosis.
• 5-HT₂A receptors, when overactive, modulate glutamate and dopamine release in downstream pathways.
• Atypical antipsychotics (clozapine, risperidone, olanzapine) are potent 5-HT₂A antagonists in addition to D2 blockers — this dual mechanism accounts for their superior tolerability and efficacy on negative symptoms.
• 5-HT₂A blockade in the mesocortical pathway can increase dopamine release in the PFC, compensating for mesocortical hypodopaminergia.

"Serotonin hyperactivity particularly at 5-HT₂A receptors... the serotonin hypothesis posits serotonergic hyperactivity particularly at cortical 5-HT₂A receptors." — Stahl's Essential Psychopharmacology

4. GABAergic Interneurons

• Parvalbumin-containing fast-spiking interneurons (PV interneurons) in the PFC and hippocampus are central to coordinating gamma-band oscillations (30–80 Hz) necessary for working memory and attention.
• These interneurons are selectively vulnerable in schizophrenia: reduced GAD67 expression decreases GABA synthesis; reduced parvalbumin expression impairs their oscillatory function.
• Loss of PV interneuron function disrupts the synchronous firing of cortical networks that underlies cognitive processing — a key mechanism linking structural abnormalities to cognitive symptoms.

5. Other Systems

III. Bioenergetic and Mitochondrial Dysfunction

• Decreased expression of GLUT1 and GLUT3 (glucose transporters) in pyramidal neurons.
• Increased cytosolic-to-mitochondrial hexokinase ratio → uncoupling of glycolysis from oxidative phosphorylation.
• Mitochondrial dysfunction reduces ATP availability in high-demand neurons, impairing the energy-intensive processes of synaptic transmission and dendritic maintenance.
• This bioenergetic failure likely underlies the progressive nature of cortical neuropil reduction.

IV. Neurodevelopmental Framework

• The brain lesion in schizophrenia is non-gliotic (no reactive gliosis) — characteristic of a prenatal or perinatal insult, not adult-onset neurodegeneration.
• Genetic variants (particularly rare, severe mutations affecting synaptic plasticity genes — e.g., DISC1, DTNBP1, NRG1, complement genes) impair normal synaptic development.
• Prenatal environmental insults (maternal infections, nutritional deficiency, obstetric complications) interact with genetic vulnerability to disturb cortical circuitry formation.
• The clinical illness emerges in adolescence/early adulthood when synaptic pruning — a normal maturational process — unmasks the pre-existing circuit deficiency.
• The PFC and hippocampus are particularly vulnerable because they are the last brain regions to mature.

• Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (Chapter 4)
• Kaplan & Sadock's Comprehensive Textbook of Psychiatry (Chapters 12.6, 12.7)
• Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 320
• Goldman-Cecil Medicine International Edition (Chapter 362)
• Ganong's Review of Medical Physiology, 26th Ed., p. 160

Anatomy & Physiology of Schizophrenia — Case Study Points

Structural Brain Changes

• Enlarged lateral and third ventricles
• Reduced gray matter volume — frontal, temporal, and parietal lobes
• Smaller pyramidal neurons with reduced dendritic spines in layer III of the DLPFC
• Reduced neuropil (synaptic connections), not neuronal loss
• ~4% hippocampal volume reduction, left-lateralized; present at onset, progressive
• Thalamic volume reduction (mediodorsal nucleus — key PFC relay)

Neurotransmitter Physiology

• Mesolimbic pathway (VTA → nucleus accumbens): hyperdopaminergia → positive symptoms (hallucinations, delusions)
• Mesocortical pathway (VTA → DLPFC): hypodopaminergia → negative & cognitive symptoms
• All antipsychotics work by blocking D2 receptors

• NMDA receptor hypofunction on GABA interneurons in PFC → loss of GABAergic inhibition → disinhibited glutamate output → downstream mesolimbic DA excess → positive symptoms
• Also produces mesocortical DA deficiency → negative/cognitive symptoms
• Explains why PCP/ketamine reproduce the full schizophrenic picture

• 5-HT₂A receptor hyperfunction at cortical neurons → contributes to psychosis
• Atypical antipsychotics (e.g., olanzapine, risperidone) block both D2 and 5-HT₂A — this improves negative symptoms by boosting PFC dopamine

• Parvalbumin interneurons dysfunctional → reduced GAD67 → disrupted cortical gamma oscillations → cognitive impairment

Other Systems

• Adenosine: reduced A1/A2A signaling → amplifies dopamine & glutamate dysregulation
• Acetylcholine: reduced M1 & α7-nAChR expression → cognitive deficits
• Cannabinoid: altered CB1 receptors; cannabis worsens positive symptoms

Bioenergetics

• Reduced glucose transporters (GLUT1/GLUT3) in DLPFC
• Mitochondrial dysfunction → impaired ATP → progressive synaptic and dendritic loss

Neurodevelopmental Core Concept

• Non-gliotic lesion = prenatal/perinatal origin, not adult neurodegeneration
• Genetic mutations impair synaptic development → illness unmasked during adolescent synaptic pruning
• PFC and hippocampus most vulnerable (last to mature)